MSRT,ISC
37
h-index
h-index
Antimicrobial Resistance in Community-Acquired Infections: A Review of Global Epidemiological Trends and Public Health Implications
Document Type : Review Article
Authors
1 Department of Pharmaceutical Quality Assurance, SSS’s Divine College of Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, 423301 SavitribaiPhule Pune University, Pune, India
2 Department of Pharmaceutical Chemistry, SSS’s Divine College of Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, 423301 SavitribaiPhule Pune University, Pune, India
10.48309/ijabbr.2026.2080069.1677
Abstract
One of the most significant global health concerns is antimicrobial resistance (AMR) in community-acquired infections (CAIs), which affects more than just hospitals. It is causing damage to public spaces on a regular basis at the moment. This review provides a critical evaluation of the etiological framework of community-acquired infections (CAIs). In addition, it emphasizes the development of resistance mechanisms in frequently encountered pathogens and investigates discrepancies in the incidence of resistance across different regions. A great deal of attention has been directed toward the growing number of bacteria that exhibit resistance to multiple drugs. These bacteria are categorized into three groups: extensively drug-resistant (XDR), pandrug-resistant (PDR), and multidrug-resistant (MDR) bacteria. This level of attention is due to the impact these bacteria have on at-risk populations, public health systems, and the effectiveness of therapies. A comprehensive examination is performed of socioeconomic factors, which encompass agricultural methods, environmental degradation, the availability of over-the-counter medications, and the excessive use of antibiotics. We investigate national and international programs that are based on frameworks for One Health and strategic action plans, in addition to examining interventions at the community level and exploring new diagnostic and therapeutic methods. The purpose of this study is to provide a strategy that is both multi-sectoral and coordinated in nature, which aims to minimize antimicrobial resistance (AMR) and preserve the effectiveness of future antimicrobial therapies. The method that is being proposed involves a combination of surveillance, stewardship, education, and innovation.
Graphical Abstract
Keywords
Subjects
OPEN ACCESS
©2026 The author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/
PUBLISHER NOTE
Sami Publishing Company remains neutral concerning jurisdictional claims in published maps and institutional affiliations.
CURRENT PUBLISHER
[1] Shallcross LJ, Davies SC. The World Health Assembly resolution on antimicrobial resistance. Journal of antimicrobial chemotherapy. 2014, 69(11), 2883-5.
[2] Shankar, P.R. Book review: Tackling drug-resistant infections globally. Archives of Pharmacy Practice, 2016, 7(3), 110-111.
[3] Mandell, L.A. Epidemiology and etiology of community-acquired pneumonia. Infectious Disease Clinics, 2004, 18(4), 761-776.
[4] Jain, N., Lodha, R., Kabra, S. Upper respiratory tract infections. The Indian Journal of Pediatrics, 2001, 68(12), 1135-1138.
[5] Flores-Mireles, A.L., Walker, J.N., Caparon, M., Hultgren, S.J. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nature Reviews Microbiology, 2015, 13(5), 269-284.
[6] Olaniyi, R., Pozzi, C., Grimaldi, L., Bagnoli, F. Staphylococcus aureus-associated skin and soft tissue infections: Anatomical localization, epidemiology, therapy and potential prophylaxis. Staphylococcus Aureus: Microbiology, Pathology, Immunology, Therapy and Prophylaxis, 2016, 199-227.
[8] Low, D.E., Keller, N., Barth, A., Jones, R.N. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: Results from the sentry antimicrobial surveillance program, 1997–1999. Clinical Infectious Diseases, 2001, 32(Supplement_2), S133-S145.
[9] Byarugaba, D.K. Mechanisms of antimicrobial resistance. Antimicrobial Resistance in Developing Countries, 2009, 15-26.
[10] Munita, J.M., Arias, C.A. Mechanisms of antibiotic resistance. Virulence Mechanisms of Bacterial Pathogens, 2016, 481-511.
[11] Donlan, R.M., Costerton, J.W. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clinical Microbiology Reviews, 2002, 15(2), 167-193.
[13] Hasan, C.M., Dutta, D., Nguyen, A.N. Revisiting antibiotic resistance: Mechanistic foundations to evolutionary outlook. Antibiotics, 2021, 11(1), 40.
[14] Schwaber, M.J., Navon-Venezia, S., Schwartz, D., Carmeli, Y. High levels of antimicrobial coresistance among extended-spectrum-β-lactamase-producing enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2005, 49(5), 2137-2139.
[15] Van Bambeke, F., Balzi, E., Tulkens, P.M. Antibiotic efflux pumps. Biochemical Pharmacology, 2000, 60(4), 457-470.
[16] Huang, L., Wu, C., Gao, H., Xu, C., Dai, M., Huang, L., Hao, H., Wang, X., Cheng, G. Bacterial multidrug efflux pumps at the frontline of antimicrobial resistance: An overview. Antibiotics, 2022, 11(4), 520.
[17] Lambert, P.A. Bacterial resistance to antibiotics: Modified target sites. Advanced Drug Delivery Reviews, 2005, 57(10), 1471-1485.
[18] Schaenzer, A.J., Wright, G.D. Antibiotic resistance by enzymatic modification of antibiotic targets. Trends in Molecular Medicine, 2020, 26(8), 768-782.
[19] O'Toole, G., Kaplan, H.B., Kolter, R. Biofilm formation as microbial development. Annual Reviews in Microbiology, 2000, 54(1), 49-79.
[20] Genco, R.J., Sanz, M. Clinical and public health implications of periodontal and systemic diseases: An overview. Periodontology 2000, 2020, 83(1), 7-13.
[21] Pons, M.J., Ruiz, J. Current trends in epidemiology and antimicrobial resistance in intensive care units. Journal of Emergency and Critical Care Medicine, 2019, 3.
[22] Agha, V., Chaurasi, M., Fatima, Z. Antibiotic resistance in who priority bacteria: South-east asia’s looming crisis. International Journal of Pharmacy Research & Technology (IJPRT), 2025, 15(1), 1044-1054.
[23] Loretz, B., Oh, Y.K., Hudson, S., Gu, Z., Lehr, C.M. Drug delivery for fighting infectious diseases: A global perspective. Drug Delivery and Translational Research, 2021, 11(4), 1316-1322.
[24] Ehsan, H. Antibiotic resistance in developing countries: Emerging threats and policy responses. Public Health Challenges, 2025, 4(1), e70034.
[25] Tadesse, B.T., Ashley, E.A., Ongarello, S., Havumaki, J., Wijegoonewardena, M., González, I.J., Dittrich, S. Antimicrobial resistance in africa: A systematic review. BMC Infectious Diseases, 2017, 17(1), 616.
[26] Leopold, S.J., van Leth, F., Tarekegn, H., Schultsz, C. Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-saharan africa: A systematic review. Journal of Antimicrobial Chemotherapy, 2014, 69(9), 2337-2353.
[27] Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.A., Klugman, K., Davies, S. Access to effective antimicrobials: A worldwide challenge. The Lancet, 2016, 387(10014), 168-175.
[28] Wi, T., Lahra, M.M., Ndowa, F., Bala, M., Dillon, J.A.R., Ramon-Pardo, P., Eremin, S.R., Bolan, G., Unemo, M. Antimicrobial resistance in neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Medicine, 2017, 14(7), e1002344.
[29] Jacobsson, S., Cole, M.J., Schröder, D., van Rensburg, M.J., Day, M., Ködmön, C., Unemo, M., Pleininger, S., Schindler, S., El-Khatib, Z. Antimicrobial resistance in neisseria gonorrhoeae and its risk groups in 23 european countries in 2022 within the european gonococcal antimicrobial surveillance programme (euro-gasp): A retrospective observational study. The Lancet Regional Health–Europe, 2025, 54.
[30] Watkins, R.R., Bonomo, R.A. Overview: The ongoing threat of antimicrobial resistance. Infectious Disease Clinics, 2020, 34(4), 649-658.
[31] Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M., Giske, C., Harbarth, S., Hindler, J., Kahlmeter, G., Olsson-Liljequist, B. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection, 2012, 18(3), 268-281.
[32] Hussein, S., Ahmed, S.K., Mohammed, S.M., Qurbani, K., Ali, S., Saber, A.F., Khdir, K., Shareef, S., Rasool, A.H., Mousa, S. Recent developments in antibiotic resistance: An increasing threat to public health–a review. Annals of Animal Science, 2025, 25(3), 981-998.
[33] Mitjà, O., Padovese, V., Folch, C., Rossoni, I., Marks, M., i Arias, M.A.R., Telenti, A., Ciuffi, A., Blondeel, K., Mårdh, O. Epidemiology and determinants of reemerging bacterial sexually transmitted infections (stis) and emerging stis in europe. The Lancet Regional Health–Europe, 2023, 34.
[34] Watkins, R.R., Bonomo, R.A. Overview: The ongoing threat of antimicrobial resistance. Infectious Disease Clinics, 2020, 34(4), 649-658.
[35] Chakrabarti, A., Balaji, V., Bansal, N., Gopalakrishnan, R., Gupta, P., Jain, A., Kale, P., Kapil, A., Prasad, K.N., Ray, P. Nams task force report on antimicrobial resistance. Ann Natl Acad Med Sci (India), 2025, 61, 171-209.
[36] Gandra, S., Joshi, J., Trett, A., Lamkang, A.S., Laxminarayan, R. Scoping report on antimicrobial resistance in india. Center for Disease Dynamics, Economics & Policy: Washington, DC, USA, 2017, 2017, 1-146.
[37] Siddique, A., Hubab, M., Rasheela, A.R.P., Samad, R., Al-Ghouti, M., Sayadi, S., Zouari, N. Microplastics and their role in the emergence of antibiotic resistance in bacteria as a threat for the environment. Environmental Chemistry and Ecotoxicology, 2025.
[38] Khan, M.S., Iqbal, M.S., Sonehri, H., Ishfaq, N., Basit, A. Antibiotic resistance: A looming threat to public health. Research Journal of Psychology, 2025, 3(2), 171-181.
[39] Fifer, H., Johnson, A. The continuing evolution of antibiotic resistance in neisseria gonorrhoeae: Past, present and future threats to effective treatment. Journal of Antimicrobial Chemotherapy, 2025, 80(5), 1213-1219.
[40] Okeke, I.N., Laxminarayan, R., Bhutta, Z.A., Duse, A.G., Jenkins, P., O'Brien, T.F., Pablos-Mendez, A., Klugman, K.P. Antimicrobial resistance in developing countries. Part i: Recent trends and current status. The Lancet Infectious Diseases, 2005, 5(8), 481-493.
[41] Vikesland, P., Garner, E., Gupta, S., Kang, S., Maile-Moskowitz, A., Zhu, N. Differential drivers of antimicrobial resistance across the world. Accounts of Chemical Research, 2019, 52(4), 916-924.
[42] Fleming-Dutra, K.E., Hersh, A.L., Shapiro, D.J., Bartoces, M., Enns, E.A., File, T.M., Finkelstein, J.A., Gerber, J.S., Hyun, D.Y., Linder, J.A. Prevalence of inappropriate antibiotic prescriptions among us ambulatory care visits, 2010-2011. Jama, 2016, 315(17), 1864-1873.
[43] Morgan, D.J., Okeke, I.N., Laxminarayan, R., Perencevich, E.N., Weisenberg, S. Non-prescription antimicrobial use worldwide: A systematic review. The Lancet Infectious Diseases, 2011, 11(9), 692-701.
[44] Ombelet, S., Ronat, J.B., Walsh, T., Yansouni, C.P., Cox, J., Vlieghe, E., Martiny, D., Semret, M., Vandenberg, O., Jacobs, J. Clinical bacteriology in low-resource settings: Today's solutions. The Lancet Infectious Diseases, 2018, 18(8), e248-e258.
[45] Väänänen, M.H., Pietilä, K., Airaksinen, M. Self-medication with antibiotics—does it really happen in europe? Health Policy, 2006, 77(2), 166-171.
[46] Singh, B., Bhat, A., Ravi, K. Antibiotics misuse and antimicrobial resistance development in agriculture: A global challenge. Environment & Health, 2024, 2(9), 618-622.
[47] Van Boeckel, T.P., Brower, C., Gilbert, M., Grenfell, B.T., Levin, S.A., Robinson, T.P., Teillant, A., Laxminarayan, R. Global trends in antimicrobial use in food animals. Proceedings of the National Academy of Sciences, 2015, 112(18), 5649-5654.
[48] Larsson, D. Pollution from drug manufacturing: Review and perspectives. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369(1656).
[49] Goossens, H., Sprenger, M.J. Community acquired infections and bacterial resistance. BMJ, 1998, 317(7159), 654-657.
[50] Shankar PR. Book review: Tackling drug-resistant infections globally. Archives of Pharmacy Practice, 2016, 7(3), 110-1.
[51] Ahmad M, Khan AU. Global economic impact of antibiotic resistance: A review. Journal of global antimicrobial resistance, 2019, 19, 313-6.
[52] Versporten, A., Bruyndonckx, R., Adriaenssens, N., Hens, N., Monnet, D.L., Molenberghs, G., Goossens, H., Weist, K., Coenen, S. Consumption of cephalosporins in the community, european union/european economic area, 1997–2017. Journal of Antimicrobial Chemotherapy, 2021, 76(Supplement_2), ii22-ii29.
[53] Singh, R., Kim, K. Environmental occurrence of antibiotic resistance, control measures and challenges in finding therapeutic management. Emerging Contaminants, 2025, 11(1), 100440.
[54] Prestinaci, F., Pezzotti, P., Pantosti, A. Antimicrobial resistance: A global multifaceted phenomenon. Pathogens and Global Health, 2015, 109(7), 309-318.
[55] Pallett, S.J., Charani, E., Hawkins, L., Mazzella, A., Anton-Vazquez, V., Banerjee, R., Evans, T.J., Patterson, B., Subbarao, S., Alqahtani, S. National action plans for antimicrobial resistance and variations in surveillance data platforms. Bulletin of the World Health Organization, 2023, 101(8), 501.
[56] World Health Organization. Antimicrobial resistance and the United Nations sustainable development cooperation framework: Guidance for United Nations Country teams, World Health Organization; 2021.
[57] Courtenay M, Castro-Sanchez E, Fitzpatrick M, Gallagher R, Lim R, Morris G. Tackling antimicrobial resistance 2019-2024 – The UK’s five-year national action plan. J Hosp Infect. 2019, 101(4), 426-427.
[58] Outterson, K., Rex, J.H., Jinks, T., Jackson, P., Hallinan, J., Karp, S., Hung, D.T., Franceschi, F., Merkeley, T., Houchens, C. Accelerating global innovation to address antibacterial resistance: Introducing carb-x. Nature Reviews Drug Discovery, 2016, 15(9), 589-590.
[59] Ajekiigbe, V.O., Ogieuhi, I.J., Odeniyi, T.A., Ogunleke, P.O., Olatunde, J.T., Babalola, A.V., Omoleke, A.A., Omitade, T.F., Olakanmi, D.E., Akingbola, A. Understanding nigeria’s antibiotic resistance crisis among neonates and its future implications. Discover Public Health, 2025, 22(1), 28.
[60] Huttner, B., Goossens, H., Verheij, T., Harbarth, S. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. The Lancet Infectious Diseases, 2010, 10(1), 17-31.
[61] Holmes, A.H., Moore, L.S., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., Guerin, P.J., Piddock, L.J. Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet, 2016, 387(10014), 176-187.
[62] Drekonja, D.M., Filice, G.A., Greer, N., Olson, A., MacDonald, R., Rutks, I., Wilt, T.J. Antimicrobial stewardship in outpatient settings: A systematic review. Infection Control & Hospital Epidemiology, 2015, 36(2), 142-152.
[63] Little, P., Stuart, B., Francis, N., Douglas, E., Tonkin-Crine, S., Anthierens, S., Cals, J.W., Melbye, H., Santer, M., Moore, M. Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: A multinational, cluster, randomised, factorial, controlled trial. The Lancet, 2013, 382(9899), 1175-1182.
[64] Huttner, B., Goossens, H., Verheij, T., Harbarth, S. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. The Lancet Infectious Diseases, 2010, 10(1), 17-31.
[65] Morgan, D.J., Okeke, I.N., Laxminarayan, R., Perencevich, E.N., Weisenberg, S. Non-prescription antimicrobial use worldwide: A systematic review. The Lancet Infectious Diseases, 2011, 11(9), 692-701.
[66] Zhu, C., Diao, Z., Yang, Y., Liao, J., Wang, C., Li, Y., Liang, Z., Xu, P., Liu, X., Zhang, Q. Recent advances and challenges in metal-based antimicrobial materials: A review of strategies to combat antibiotic resistance. Journal of Nanobiotechnology, 2025, 23(1), 193.
[67] Theuretzbacher, U., Outterson, K., Engel, A., Karlén, A. The global preclinical antibacterial pipeline. Nature Reviews Microbiology, 2020, 18(5), 275-285.
[68] Schlagenhauf, P., Deuel, J. Concerts and covid: Can the beat go on? The Lancet Infectious Diseases, 2022, 22(3), 299-301.
[69] Alcaro, S., Alteri, C., Artese, A., Ceccherini-Silberstein, F., Costa, G., Ortuso, F., Parrotta, L., Perno, C.F., Svicher, V. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of hiv-1 reverse transcriptase. Drug Resistance Updates, 2011, 14(3), 141-149.
[70] Rawson, T.M., Ahmad, R., Toumazou, C., Georgiou, P., Holmes, A.H. Artificial intelligence can improve decision-making in infection management. Nature Human Behaviour, 2019, 3(6), 543-545.
[71] Dar, O.A., Hasan, R., Schlundt, J., Harbarth, S., Caleo, G., Dar, F.K., Littmann, J., Rweyemamu, M., Buckley, E.J., Shahid, M. Exploring the evidence base for national and regional policy interventions to combat resistance. The Lancet, 2016, 387(10015), 285-295.
Articles in Press, Accepted Manuscript
Available Online from 16 February 2026
- Receive Date 06 December 2025
- Revise Date 02 January 2026
- Accept Date 03 February 2026
| Article View | 42 |
| PDF Download | 41 |